Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020-2026
Feredj, E.; Zhang, Q.; Bastard, P.; Casanova, J.-L.; Cobat, A.
Show abstract
Autoantibodies neutralizing type I IFNs (AAN-IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto-Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN-IFN-I was estimated at 7.9% (95% CI, 6.0-10.4). Disease severity was strongly associated with AAN-IFN-I prevalence (OR, 11.7; 95%CI, 7.6-17.9; P=5x10^-29). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2-12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1-19.2%) in those who died. The prevalence of AAN-IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease 92%
- SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection 91%
- Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity 91%
Similar papers in this journal
- IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study 91%
- sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies 91%
- Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity 91%
Similar papers in this journal
- A prospective study of the protective effect of SARS-CoV-2–specific antibodies and T cells in Moscow residents 90%
- Decline in pneumococcal disease in young children during the COVID-19 pandemic associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: A prospective cohort study 90%
- High frequency of SARS-CoV-2 RNAemia and association with severe disease 90%
Similar papers in this journal
- Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later 90%
- Influenza-Negative Influenza-Like Illness (fnILI) Z-Score as a Proxy for Incidence and Mortality of COVID-19 90%
- Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial 90%
Similar papers in this journal
- A unique dexamethasone-dependent gene expression profile in the lungs of COVID-19 patients 91%
- The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members 90%
- Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.